Editorial: Cellular and phenotypic plasticity in cancer

Frontiers in Oncology

Volumn 5, Issue Aug, 2015, Pages

  Ferrao, Petranel T ^a,b   Behren, Andreas ^c   Anderson, Robin L ^a,b   Thompson, Erik W ^d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^d QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Cancer; Cross talk; Drug resistance; Epithelial mesenchymal transition (EMT); Exosomes; Immune system; Phenotypic plasticity; Signaling pathways

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR;

BREAST CANCER; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; DNA DAMAGE; DRUG RESPONSE; EDITORIAL; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; NEOPLASM; NERVE CELL PLASTICITY; PHENOTYPIC PLASTICITY; PROTEIN EXPRESSION; PROTEOMICS; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84939798015     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00171     Document Type: Editorial

References (20)

1. Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal (2014) 7:re8. doi: 10.1126/scisignal.2005189.
2. Lindsey S, Langhans SA. Crosstalk of oncogenic signaling pathways during epithelial-mesenchymal transition. Front Oncol (2014) 4:358. doi:10.3389/fonc.2014.00358.
3. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 119:1420-8. doi:10.1172/JCI39104.
4. McInnes LM, Jacobson N, Redfern A, Dowling A, Thompson EW, Saunders CM. Clinical implications of circulating tumor cells of breast cancer patients: role of epithelial-mesenchymal plasticity. Front Oncol (2015) 5:42. doi:10.3389/fonc.2015.00042.
5. Pereira L, Mariadason JM, Hannan RD, Dhillon AS. Implications of epithelial-mesenchymal plasticity for heterogeneity in colorectal cancer. Front Oncol (2015) 5:13. doi:10.3389/fonc.2015.00013.
6. Hoek KS, Goding CR. Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res (2010) 23:746-59. doi:10.1111/j.1755-148X.2010.00757.x.
7. Li FZ, Dhillon AS, Anderson RL, McArthur G, Ferrao PT. Phenotype switching in melanoma: implications for progression and therapy. Front Oncol (2015) 5:31. doi:10.3389/fonc.2015.00031.
8. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol (2006) 172:973-81. doi:10.1083/jcb.200601018.
9. van Denderen BJ, Thompson EW. Cancer: the to and fro of tumour spread. Nature (2013) 493:487-8. doi:10.1038/493487a.
10. Woods K, Pasam A, Jayachandran A, Andrews MC, Cebon J. Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells. Front Oncol (2014) 4:367. doi:10.3389/fonc.2014.00367.
11. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science (2013) 339:580-4. doi:10.1126/science.1228522.
12. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 106:13820-5. doi:10.1073/pnas.0905718106.
13. Nouri M, Ratther E, Stylianou N, Nelson CC, Hollier BG, Williams ED. Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention. Front Oncol (2014) 4:370. doi:10.3389/fonc.2014.00370.
14. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell (2009) 138:645-59. doi:10.1016/j.cell.2009.06.034.
15. Parker R, Vella LJ, Xavier D, Amirkhani A, Parker J, Cebon J, et al. Phosphoproteomic analysis of cell-based resistance to BRAF inhibitor therapy in melanoma. Front Oncol (2015) 5:95. doi:10.3389/fonc.2015.00095.
16. Vella LJ. The emerging role of exosomes in epithelial-mesenchymal-transition in cancer. Front Oncol (2014) 4:361. doi:10.3389/fonc.2014.00361.
17. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med (2012) 18:883-91. doi:10.1038/nm.2753.
18. Anastas JN, Kulikauskas RM, Tamir T, Rizos H, Long GV, von Euw EM, et al. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. J Clin Invest (2014) 124:2877-90. doi:10.1172/JCI70156.
19. Smit MA, Maddalo G, Greig K, Raaijmakers LM, Possik PA, van Breukelen B, et al. ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma. Mol Syst Biol (2014) 10:772. doi:10.15252/msb.20145450.
20. Jayachandran A, McKeown SJ, Woods BL, Prithviraj P, Cebon J. Embryonic chicken transplantation is a promising model for studying the invasive behavior of melanoma cells. Front Oncol (2015) 5:36. doi:10.3389/fonc.2015.00036.